No Detail Found!

Comparison of inflammatory control and safety by timing of doxycycline-azithromycin dual therapy in pediatric mycoplasmal pneumonia

Author(s)
Mei Han Department of Pediatrics, Lixin County People's Hospital,Bozhou, Anhui,China
Abstract
The therapeutic approach of combining doxycycline (DOX) with azithromycin (AZM) has emerged as an effective strategy for managing pediatric Mycoplasmal pneumonia (MP), with its clinical efficacy well-established. It is worth noting that both DOX and AZM are antibiotics and require an interval of 24-72 hours when used in combination, but there are few studies on the optimal interval between the two drugs. This study aimed to elucidate the differential outcomes of two treatment regimens. The short-term group received DOX in combination with AZM within 24-72 hours after AZM administration for MP treatment, while the long-term group initiated DOX therapy more than 72 hours after AZM treatment. Our findings indicated that there were no statistically significant differences in clinical efficacy and the impact on pediatric pulmonary function between the two groups (P>0.05). However, the time for symptom improvement in the short-term group was significantly shortened (P<0.05), while the long-term group exhibited lower inflammatory responses, stress responses and a reduced incidence of complications (P<0.05). In conclusion, initiating DOX within 72 hours after AZM treatment can expedite the treatment course of MP, while using DOX more than 72 hours after AZM treatment confers enhanced safety.
Publication Details
Page(s) 2264-2270
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 38, Issue: 6, Year: 2025

Request the full text from PASTIC

Keywords
Stress response, Azithromycin, Lung function, Doxycycline, inflammatory factors, Mycoplasmal pneumonia
References
Allinson JP,Vlies BH,Brill SE,Law M,Burnside G,Finney LJ,Alves-Moreira L,Donaldson GC,Calverley PMA,Walker PP,Wedzicha JA PP .2023 .A doubleblind, randomized, placebo-controlled trial of long-term doxycycline therapy on exacerbation rate in patients with stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med, 208(5) : 549-558.
Apato A,Cruz SN,Desai D,Slocum GW .2024 .Doxycycline adherence for the management of Chlamydia trachomatis infections. Am. J. Emerg. Med, 81 : 136-139.
Chen CJ,Gillett A,Booth R,Kimble B,Govendir M .2022 .Pharmacokinetic profile of doxycycline in koala plasma after weekly subcutaneous injections for the treatment of chlamydiosis. Animals, 12(3) : 250.
Chen Y,Zhang Y,Tang QN,Shi HB .2024 .Efficacy of doxycycline therapy for macrolide-resistant Mycoplasma pneumoniae pneumonia in children at different periods. Ital. J. Pediatr., 50(1) : 38.
Cheng J,Liu Y,Zhang G,Tan L,Luo Z L .2024 .Azithromycin effectiveness in children with mutated Mycoplasma pneumoniae Pneumonia. , 17 : 2933-2942.
Ding G,Zhang X,Vinturache A,van Rossum AMC,Yin Y,Zhang Y .2024 .Challenges in the treatment of pediatric Mycoplasma pneumoniae pneumonia. Eur. J. Pediatr., 183(7) : 3001-3011.
Drozdzal S,Rosik J,Lechowicz K,Machaj F,Kotfis K,Ghavami S,Los MJ S .2020 .FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. , 53 : 100719.
Fan G,Guo Y,Tang F,Chen M,Liao S,Wang J .2023 .Determining the clinical characteristics, treatment strategies and prognostic factors for Mycoplasma pneumoniae encephalitis in children: A multicenter study in china. J. Clin. Neurol, 19(4) : 402-409.
Kinney Greco,Kovacic Scherrer A,Sarkar N,Jain S,Wen P,Hadique S S .2023 .beta-Lactams plus doxycycline versus azithromycin for treatment of severe communityacquired pneumonia in critically ill patients. J. Antimicrob. Chemother., 78(12) : 2816-2823.
Kabir KI,John J,Satapathy AK,Sahu S,Behera B,Padhy BM B .2022 .Oral azithromycin versus doxycycline in the treatment of children with uncomplicated scrub typhus: A randomized controlled trial. Pediatr. Infect. Dis. J., 41(3) : 224-229.
Kim K,Jung S,Kim M,Park S,Yang HJ,Lee E .2022 .Global trends in the proportion of macrolide-resistant Mycoplasma pneumoniae infections: A systematic review and meta-analysis. JAMA Netw, 5(7) : e2220949.
Lee H,Choi YY,Sohn YJ,Kim YK,Han MS,Yun KW,Kim K,Park JY,Choi JH,Cho EY,Choi EH .2021 .Clinical efficacy of doxycycline for treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. Antibiotics, 10(2) : 192.
Li J,Zhang H,Guo J,Ma X .2024 .Clinical features of Mycoplasma pneumoniae pneumonia in children without fever. BMC Pediatr, 24(1) : 52.
Lu Z,Hou M,Li D,Cheng J,Deng H,Yan J .2020 .Azithromycin combined with doxycycline in nongonococcal urethritis. Exp. Ther. Med, 20(4) : 3887-3894.
Luo XQ,Luo J,Wang CJ,Luo ZX,Tian DY,Xie XH .2023 .Clinical features of severe Mycoplasma pneumoniae pneumonia with pulmonary complications in childhood: A retrospective study. Pediatr. Pulmonol., 58(10) : 2815-2822.
Okic Dordevic I,Kukolj T,Zivanovic M,Momcilovic S,Obradovic H,Petrovic A,Mojsilovic S,Trivanovic D,Jaukovic A .2023 .The role of doxycycline and il17 in regenerative potential of periodontal ligament stem cells: Implications in periodontitis. , 13(10) : 1437.
Song X,Zhou N,Lu S,Gu C,Qiao X C .2024 .Newgeneration tetracyclines for severe macrolide-resistant Mycoplasma pneumoniae pneumonia in children: A retrospective analysis. BMC Infect. Dis., 24(1) : 1166.
Streekstra EJ,Keuper-Navis M,van den Broek P,Greupink R,Stommel MWJ,de Boode WP,Botden S,Russel FGM,de Wildt SN FGM .2024 .The potential of enteroids derived from children and adults to study age-dependent differences in intestinal CYP3A4/5 metabolism. Eur. J. Pharm. Sci., 201 : 106868.
Todkill D,Lamagni T,Pebody R,Ramsay M,Woolham D,Demirjian A,Salzmann A,Chand M,Hughes HE,Bennett C,Hope R,Watson CH,Brown CS,Elliot AJ .2023 .Persistent elevation in incidence of pneumonia in children in England,. , 29(32) : 2000485.
Tsalik EL,Rouphael NG,Sadikot RT,Rodriguez-Barradas MC,McClain MT,Wilkins DM,Woods CW,Swamy GK,Walter EB,El Sahly HM,Keitel WA,Mulligan MJ,Tuyishimire B,Serti E,Hamasaki T,Evans SR,Ghazaryan V,Lee MS,Lautenbach E,Group T-LS .2023 .Efficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: A randomised, placebo-controlled, double-blind, non-inferiority trial. Lancet Infect. Dis., 23(4) : 484-495.
Viteri-Davila C,Morales-Jadan D,Creel A,Jop Vidal AG,Boldo XM,Rivera-Olivero IA,Bautista-Munoz C,Alibayov B,Garcia-Bereguiain MA,Vidal JE .2024 .The crisis of macrolide resistance in pneumococci in latin america. Am. J. Trop. Med, 111(4) : 756-764.
Xie Q,Zhang X,Cui W,Pang Y .2022 .Construction of a nomogram for identifying refractory Mycoplasma pneumoniae pneumonia among macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children. J. Inflamm. Res., 15 : 6495-6504.
0

Citations

0

Downloads

123

Views